Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 25 versus MAVIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 25 versus MAVIK.
CAPOZIDE 50/25 vs MAVIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Category C
Category C
ACE Inhibitor/Diuretic Combination
ACE Inhibitor